ABVC BioPharma, Inc.
ABVCABVC BioPharma is an early-stage biotechnology company focused on developing innovative botanical drugs and medical devices for central nervous system (CNS) and oncology/hematology diseases.
Table of contents
Earnings
Next report
Date not yet announcedCompetitors
By market cap
Profile
ABVC BioPharma is an early-stage biotechnology company focused on developing innovative botanical drugs and medical devices for central nervous system (CNS) and oncology/hematology diseases. The company identifies promising medical discoveries from research institutions in the Asia-Pacific region and advances them through clinical trials, primarily targeting unmet medical needs in depression, ADHD, and various cancers. Its core value proposition lies in its integrated approach, combining in-house GMP manufacturing capabilities with a strategic out-licensing model for late-stage commercialization.
An early-stage developer leveraging botanical-based active ingredients and a regional focus on Asia-Pacific research to build a niche pipeline in CNS and oncology.
Questions, answered.
- What is ABVC BioPharma, Inc.'s market cap?
- ABVC BioPharma, Inc. (ABVC) has a market capitalization of $37.7M and trades on NASDAQ.
- Who are ABVC BioPharma, Inc.'s competitors?
- ABVC BioPharma, Inc.'s key competitors include Eli Lilly and Co., Pfizer Inc., Novartis AG, and others. These companies compete in similar markets and product categories.
- Who does ABVC BioPharma, Inc. partner with?
- ABVC BioPharma, Inc.'s notable partners include Rgene Corporation, Define Biotech Co. Ltd., Shogun Maitake Canada, Co. Ltd., and others.
- What subsidiaries does ABVC BioPharma, Inc. have?
- ABVC BioPharma, Inc.'s subsidiaries include BioKey, Inc., BriVision, BioLite Holding, Inc., and others.
- Where is ABVC BioPharma, Inc. headquartered?
- ABVC BioPharma, Inc. is headquartered in United States of America and employs approximately 19 people. It has been publicly traded since 2004.